Possible Biomarkers for Cancer Immunotherapy

Immune checkpoint inhibitors (ICIs) have drastically changed the clinical care of cancer. Although cancer immunotherapy has shown promise in various types of malignancies, thus far, the proportion of patients who can benefit from ICIs is relatively small. Immune-related adverse events and high cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Otoshi, Takehiro, Nagano, Tatsuya, Tachihara, Motoko, Nishimura, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678720/
https://www.ncbi.nlm.nih.gov/pubmed/31277279
http://dx.doi.org/10.3390/cancers11070935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678720/
https://www.ncbi.nlm.nih.gov/pubmed/31277279
http://dx.doi.org/10.3390/cancers11070935

Ejemplares similares